Thirty Technology joins the fight against antibiotic resistant infection.
30 Technology enters into a strategic Licencing Agreement to develop new treatments for multi-drug resistant tuberculosis
read more
30 Technology
30 Technology launches a critical clinical trial of RESP301 in cystic fibrosis patients with serious lung infections
RESP301 to combat antibiotic resistant/refractory infection in people with cystic fibrosis
Thirty Respiratory receives approval for multicentre post-exposure clinical trial of RESP301 to prevent transmission of COVID-19 in the community
Break-through new treatment to protect people at risk from COVID-19
30 Technology announces first patients enrolled in UK clinical trial (NOCoV2) for the treatment of COVID-19
Thirty Respiratory Ltd (“30 Technology”) announced today that the first patients have been enrolled in the multicentre Phase 2/3 NOCoV2 trial of its leading antiviral product, RESP301, as a treatment for patients hospitalised with COVID-19.